The US government—through the NIH (National Institutes of Health) or DARPA (the Defense Department's research agency)—will announce at least $50 million in new research grants for ibogaine and brain plasticity studies by late 2027. This matters because government funding signals that ibogaine is moving from fringe to mainstream science, and the money enables labs to do expensive mechanistic research.
Juvenile-like plasticity restoration (BDNF/TrkB signaling, perineuronal net remodeling) is a credible and high-value finding with dual-use applications for TBI and cognitive restoration. DARPA has funded analogous plasticity research. NIH HEAL has existing ibogaine infrastructure grants. However, $50M is a specific and large threshold; NIH grant cycles are 12-18 months from announcement to award, and DARPA program creation requires internal approval. Tracking this requires public grant database verification (NIH Reporter, USASpending.gov). Confidence reduced from 0.77—the directional claim is plausible but the dollar threshold and timeline make this harder to achieve.